

# Marina Berenguer

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2034239/marina-berenguer-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

184  
papers

10,305  
citations

49  
h-index

99  
g-index

253  
ext. papers

12,059  
ext. citations

4.3  
avg, IF

6.38  
L-index

#	Paper	IF	Citations
184	The ILTS-SETH Consensus Conference on Extrahepatic Cancer and Liver Transplantation: Paving the Way.. <i>Transplantation</i> , <b>2022</b> , 106, e1-e2	1.8	1
183	Cytomegalovirus specific polyfunctional T-cell responses expressing CD107a predict control of CMV infection after liver transplantation. <i>Cellular Immunology</i> , <b>2021</b> , 371, 104455	4.4	0
182	Global impact of the first wave of COVID-19 on liver transplant centers: A multi-society survey (EASL-ESOT/ELITA-ILTS). <i>Journal of Hepatology</i> , <b>2021</b> ,	13.4	5
181	Long-term outcome after living donor liver transplantation compared to donation after brain death in autoimmune liver diseases: Experience from the European Liver Transplant Registry. <i>American Journal of Transplantation</i> , <b>2021</b> ,	8.7	2
180	Transplant Oncology in Primary and Metastatic Liver Tumors: Principles, Evidence, and Opportunities. <i>Annals of Surgery</i> , <b>2021</b> , 273, 483-493	7.8	11
179	Characteristics, Trends, and Outcomes of Liver Transplantation for Primary Sclerosing Cholangitis in Female Versus Male Patients: An Analysis From the European Liver Transplant Registry. <i>Transplantation</i> , <b>2021</b> , 105, 2255-2262	1.8	4
178	Characteristics and impact of sex in a cohort of patients with primary sclerosing cholangitis: Experience of a transplant center in the Mediterranean basin. <i>Gastroenterología Y Hepatología</i> , <b>2021</b> ,	0.9	1
177	Frailty and Sarcopenia in Acute-on-Chronic Liver Failure. <i>Hepatology Communications</i> , <b>2021</b> , 5, 1333-1347	7	1
176	Emerging Management of Hepatitis C in Transplant <b>2021</b> , 951-969		
175	Cardiovascular risk and liver transplantation in HIV patients. Are HIV infected liver transplant recipients at higher risk?. <i>Journal of Liver Transplantation</i> , <b>2021</b> , 1, 100005		
174	Hepatic steatosis and steatohepatitis: a functional meta-analysis of sex-based differences in transcriptomic studies. <i>Biology of Sex Differences</i> , <b>2021</b> , 12, 29	9.3	0
173	Wilson's Disease: Facing the Challenge of Diagnosing a Rare Disease. <i>Biomedicines</i> , <b>2021</b> , 9,	4.8	7
172	Longterm Survival After Liver Transplantation for Autoimmune Hepatitis: Results From the European Liver Transplant Registry. <i>Liver Transplantation</i> , <b>2020</b> , 26, 866-877	4.5	11
171	Genetics of Wilson disease and Wilson-like phenotype in a clinical series from eastern Spain. <i>Clinical Genetics</i> , <b>2020</b> , 97, 758-763	4	9
170	A population-based screening for hepatitis C antibodies and active infection using a point-of-care test in a low prevalence area. <i>PLoS ONE</i> , <b>2020</b> , 15, e0228351	3.7	5
169	Emerging Management of Hepatitis C in Transplant <b>2020</b> , 1-20		
168	Changing delta hepatitis patient profile: A single center experience in Valencia region, Spain. <i>World Journal of Hepatology</i> , <b>2020</b> , 12, 277-287	3.4	2

167	Gender Disparities in Liver Transplantation <b>2020</b> , 329-339		0
166	Immunosuppression in liver transplant. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2020</b> , 46-47, 101681	2.5	12
165	Posttransplant Management of Recipients Undergoing Liver Transplantation for Hepatocellular Carcinoma. Working Group Report From the ILTS Transplant Oncology Consensus Conference. <i>Transplantation</i> , <b>2020</b> , 104, 1143-1149	1.8	10
164	The Authors Reply: Tacrolimus Trough Concentrations After Liver Transplantation: Back to the Future. <i>Transplantation</i> , <b>2020</b> , 104, e115-e116	1.8	
163	Posttransplant Calcineurin Inhibitors Levels and Inpatient Variability Are Not Associated With Long-term Outcomes Following Liver Transplantation. <i>Transplantation</i> , <b>2020</b> , 104, 1201-1209	1.8	0
162	Temporal Trends and Outcomes in Liver Transplantation for Recipients With HIV Infection in Europe and United States. <i>Transplantation</i> , <b>2020</b> , 104, 2078-2086	1.8	13
161	COVID-19 and liver transplantation. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2020</b> , 17, 526-528	24.2	30
160	The Impact of Direct-acting Antivirals on Overall Mortality and Tumoral Recurrence in Patients With Hepatocellular Carcinoma Listed for Liver Transplantation: An International Multicenter Study. <i>Transplantation</i> , <b>2020</b> , 104, 2087-2096	1.8	7
159	EASL recommendations on treatment of hepatitis C: Final update of the series. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 1170-1218	13.4	237
158	Post-transplantation outcome in non-alcoholic steatohepatitis cirrhosis: Comparison with alcoholic cirrhosis. <i>Annals of Hepatology</i> , <b>2019</b> , 18, 855-861	3.1	9
157	Presentation and Outcomes of Pregnancy in Patients With Autoimmune Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 2819-2821	6.9	11
156	Long-term outcomes of the octogenarian donor liver recipient: The era of the new centurion. <i>Clinical Transplantation</i> , <b>2019</b> , 33, e13629	3.8	2
155	Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). <i>Gastroenterología Y Hepatología (English Edition)</i> , <b>2019</b> , 42, 579-592	0.1	2
154	Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). <i>Revista Espanola De Enfermedades Digestivas</i> , <b>2019</b> , 111, 862-873	0.9	4
153	Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). <i>Gastroenterología Y Hepatología</i> , <b>2019</b> , 42, 579-592	0.9	13
152	Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus Infection in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2018 Clinical Practice Guideline. <i>Annals of Internal Medicine</i> , <b>2019</b> , 171, 496-504	8	11
151	The ILTS Consensus Conference on NAFLD/NASH and Liver Transplantation: Setting the Stage. <i>Transplantation</i> , <b>2019</b> , 103, 19-21	1.8	6
150	Equally Interchangeable? How Sex and Gender Affect Transplantation. <i>Transplantation</i> , <b>2019</b> , 103, 1094-1100	1.8	35

149	Milan-out Criteria and Worse Intention-to-Treat Outcome Postliver Transplantation. <i>Transplantation Direct</i> , <b>2019</b> , 5, e487	2.3	0
148	International Liver Transplantation Consensus Statement on End-stage Liver Disease Due to Nonalcoholic Steatohepatitis and Liver Transplantation. <i>Transplantation</i> , <b>2019</b> , 103, 45-56	1.8	42
147	International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients. <i>Transplantation</i> , <b>2018</b> , 102, 727-743	1.8	84
146	Cytomegalovirus reactivation in liver transplant recipients due to hepatitis C cirrhosis is associated with higher cardiovascular risk - an observational, retrospective study. <i>Transplant International</i> , <b>2018</b> , 31, 649-657	3	6
145	Should organs from hepatitis C-positive donors be used in hepatitis C-negative recipients for liver transplantation?. <i>Liver Transplantation</i> , <b>2018</b> , 24, 831-840	4.5	25
144	Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. <i>Gastroenterología Y Hepatología</i> , <b>2018</b> , 41, 328-349	0.9	30
143	EASL Recommendations on Treatment of Hepatitis C 2018. <i>Journal of Hepatology</i> , <b>2018</b> , 69, 461-511	13.4	1079
142	Liver Volume as a Predictor of Functional Improvement Post-DAA Treatment. <i>Transplantation</i> , <b>2018</b> , 102, e74-e81	1.8	7
141	Introduction to hepatitis C virus infection: Overview and history of hepatitis C virus therapies. <i>Hemodialysis International</i> , <b>2018</b> , 22 Suppl 1, S8-S21	1.7	19
140	Performance of the OraQuick Hepatitis C virus antibody test in oral fluid and fingerstick blood before and after treatment-induced viral clearance. <i>Journal of Clinical Virology</i> , <b>2018</b> , 102, 77-83	14.5	27
139	Significant impact of new oral therapies against HCV on the waiting list for liver transplantation in Spain. <i>Journal of Hepatology</i> , <b>2018</b> , 69, 966-968	13.4	12
138	Delisting HCV-infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting. <i>Liver International</i> , <b>2018</b> , 38, 2170-2177	7.9	36
137	Remnant vital tissue following locoregional therapy for hepatocellular carcinoma: another player in the game. <i>Transplant International</i> , <b>2018</b> , 31, 972	3	1
136	Fat and liver transplantation: clinical implications. <i>Transplant International</i> , <b>2018</b> , 31, 828-837	3	10
135	Impact of hepatitis C virus (HCV) antiviral treatment on the need for liver transplantation (LT). <i>Liver International</i> , <b>2018</b> , 38, 1022-1027	7.9	13
134	Primary biliary cholangitis in Spain. Results of a Delphi study of epidemiology, diagnosis, follow-up and treatment. <i>Revista Espanola De Enfermedades Digestivas</i> , <b>2018</b> , 110, 641-649	0.9	2
133	Delisting of Liver Transplant Candidates with Chronic HCV Infection after Viral Eradication. <i>Transplantation</i> , <b>2018</b> , 102, S3	1.8	
132	Peritransplant Antiviral Treatment of Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients. <i>Liver Transplantation</i> , <b>2018</b> , 24, 1476-1480	4.5	1

131	Guidelines on treatment of hepatitis C virus infection. Spanish Association for the Study of the Liver (AEEH). <i>Gastroenterología Y Hepatología</i> , <b>2018</b> , 41, 597-608	0.9	10
130	Stretching the boundaries for liver transplant in the 21st century. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2018</b> , 3, 803-811	18.8	15
129	Executive summary of the 2018 KDIGO Hepatitis C in CKD Guideline: welcoming advances in evaluation and management. <i>Kidney International</i> , <b>2018</b> , 94, 663-673	9.9	54
128	Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. <i>Gastroenterología Y Hepatología (English Edition)</i> , <b>2018</b> , 41, 328-349	0.1	1
127	The road map toward an hepatitis C virus-free transplant population. <i>American Journal of Transplantation</i> , <b>2018</b> , 18, 2409-2416	8.7	2
126	Hepatitis C-related cirrhosis. Current status. <i>Medicina Clínica</i> , <b>2017</b> , 148, 78-85	1	5
125	Hepatitis C-related cirrhosis. Current status. <i>Medicina Clínica (English Edition)</i> , <b>2017</b> , 148, 78-85	0.3	0
124	An objective definition for clinical suspicion of T-cell-mediated rejection after liver transplantation. <i>Clinical Transplantation</i> , <b>2017</b> , 31, e13005	3.8	7
123	Disease Reversibility in Patients With Post-Hepatitis C Cirrhosis: Is the Point of No Return the Same Before and After Liver Transplantation? A Review. <i>Transplantation</i> , <b>2017</b> , 101, 916-923	1.8	14
122	International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates. <i>Transplantation</i> , <b>2017</b> , 101, 945-955	1.8	63
121	International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Recipients. <i>Transplantation</i> , <b>2017</b> , 101, 956-967	1.8	40
120	Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase II SATURN study. <i>Transplant Infectious Disease</i> , <b>2017</b> , 19, e12696	2.7	10
119	The New Era of Hepatitis C: Therapy in Liver Transplant Recipients. <i>Clinics in Liver Disease</i> , <b>2017</b> , 21, 421-434	4.4	5
118	ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 585-602	13.4	57
117	Delisting of liver transplant candidates with chronic hepatitis C virus infection after viral eradication: outcome after delisting: a European study. <i>Journal of Hepatology</i> , <b>2017</b> , 66, S39-S40	13.4	2
116	Pilot validation study of a rapid test in oral fluid for population screening of hepatitis C virus infection. <i>Journal of Hepatology</i> , <b>2017</b> , 66, S403-S404	13.4	2
115	Combined resistance and endurance training at a moderate-to-high intensity improves physical condition and quality of life in liver transplant patients. <i>Liver Transplantation</i> , <b>2017</b> , 23, 1273-1281	4.5	26
114	Pushing the donor limits: Deceased donor liver transplantation using organs from octogenarian donors. <i>Liver Transplantation</i> , <b>2017</b> , 23, S22-S26	4.5	9

113	Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir/Sofosbuvir Plus Ribavirin Pretransplant. <i>Annals of Hepatology</i> , <b>2017</b> , 16, 322-323	3.1	
112	Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir/Sofosbuvir Plus Ribavirin Pretransplant. <i>Annals of Hepatology</i> , <b>2017</b> , 16, 322-323	3.1	
111	Iberogast-Induced Severe Hepatotoxicity Leading to Liver Transplantation. <i>American Journal of Gastroenterology</i> , <b>2016</b> , 111, 1364-5	0.7	15
110	Reversion of disease manifestations after HCV eradication. <i>Journal of Hepatology</i> , <b>2016</b> , 65, S95-S108	13.4	108
109	Liver Websites. <i>Transplantation</i> , <b>2016</b> , 100, 1594	1.8	
108	HCV Recurrence: Predictors and Outcomes After Liver Transplantation <b>2016</b> , 35-54		
107	Predictive factors for survival and score application in liver retransplantation for hepatitis C recurrence. <i>World Journal of Gastroenterology</i> , <b>2016</b> , 22, 4547-58	5.6	11
106	Liver Transplantation for Alcoholic Liver Disease. <i>Transplantation</i> , <b>2016</b> , 100, 981-7	1.8	44
105	Controlling Diabetes After Liver Transplantation: Room for Improvement. <i>Transplantation</i> , <b>2016</b> , 100, e66-e73	1.8	11
104	Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. <i>Journal of Hepatology</i> , <b>2016</b> , 65, 524-31	13.4	235
103	Last gasps of the hepatitis C virus dragon: Direct acting antiviral failures and hepatitis C virus-positive donors. <i>Liver Transplantation</i> , <b>2016</b> , 22, 47-51	4.5	1
102	Efficacy of telaprevir-based therapy in stable liver transplant patients with chronic genotype 1 hepatitis C. <i>Annals of Hepatology</i> , <b>2016</b> , 15, 512-23	3.1	1
101	Management of HCV in the liver transplant setting. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2015</b> , 39 Suppl 1, S115-9	2.4	5
100	Outcomes in liver transplantation: does sex matter?. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 946-55	13.4	51
99	O004 : On-treatment virologic response and tolerability of simeprevir, daclatasvir and ribavirin in patients with recurrent hepatitis c virus genotype 1b infection after orthotopic liver transplantation (OLT): Interim data from the phase II saturn study. <i>Journal of Hepatology</i> , <b>2015</b> , 62, S191-S192	13.4	12
98	Transplantation for Hepatitis C <b>2015</b> , 131-152		
97	Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. <i>Lancet, The</i> , <b>2015</b> , 385, 2502-9	4.0	220
96	Overcoming drug resistance in HSV, CMV, HBV and HCV infection. <i>Future Microbiology</i> , <b>2015</b> , 10, 1759-66.9		4

95	Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia. <i>Liver International</i> , <b>2015</b> , 35, 2358-62	7.9	14
94	Alterations in carbohydrate metabolism in cirrhotic patients before and after liver transplant. <i>Diabetes Research and Clinical Practice</i> , <b>2015</b> , 110, 123-8	7.4	4
93	Acute cellular rejection versus recurrent hepatitis C after liver transplantation: Clinical and pathological features driving a rational diagnostic approach. <i>Hepatology Research</i> , <b>2015</b> , 45, 423-31	5.1	4
92	Impact of anticoagulation on upper-gastrointestinal bleeding in cirrhosis. A retrospective multicenter study. <i>Hepatology</i> , <b>2015</b> , 62, 575-83	11.2	78
91	Framingham score, renal dysfunction, and cardiovascular risk in liver transplant patients. <i>Liver Transplantation</i> , <b>2015</b> , 21, 812-22	4.5	26
90	Beyond cure: preventing and managing the complications of end-stage liver disease. <i>Current Opinion in HIV and AIDS</i> , <b>2015</b> , 10, 355-60	4.2	1
89	High efficacy and safety of triple therapy in HCV genotype 1 and moderate fibrosis: a multicenter study of clinical practice in Spain. <i>Annals of Hepatology</i> , <b>2015</b> , 14, 477-486	3.1	1
88	High efficacy and safety of triple therapy in HCV genotype 1 and moderate fibrosis: a multicenter study of clinical practice in Spain. <i>Annals of Hepatology</i> , <b>2015</b> , 14, 477-86	3.1	
87	Liver. <i>American Journal of Gastroenterology</i> , <b>2014</b> , 109 Suppl 2, S123-87	0.7	4
86	Computational models of liver fibrosis progression for hepatitis C virus chronic infection. <i>BMC Bioinformatics</i> , <b>2014</b> , 15 Suppl 8, S5	3.6	16
85	Reply to: "Renal impairment and anemia during triple therapy". <i>Journal of Hepatology</i> , <b>2014</b> , 60, 1100-1	13.4	1
84	Improved renal function in liver transplant recipients treated for hepatitis C virus with a sustained virological response and mild chronic kidney disease. <i>Liver Transplantation</i> , <b>2014</b> , 20, 25-34	4.5	28
83	HCV-induced immune responses influence the development of operational tolerance after liver transplantation in humans. <i>Science Translational Medicine</i> , <b>2014</b> , 6, 242ra81	17.5	60
82	Management of anemia induced by triple therapy in patients with chronic hepatitis C: challenges, opportunities and recommendations. <i>Journal of Hepatology</i> , <b>2013</b> , 59, 1323-30	13.4	29
81	Long-term outcome of long-term liver transplant survivors. <i>Transplant International</i> , <b>2013</b> , 26, 740-50	3	37
80	Efficacy of the retreatment of hepatitis C virus infections after liver transplantation: role of an aggressive approach. <i>Liver Transplantation</i> , <b>2013</b> , 19, 69-77	4.5	17
79	Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment. <i>Journal of Hepatology</i> , <b>2013</b> , 58, 1028-41	13.4	111
78	Chronic kidney disease after liver transplantation: pretransplantation risk factors and predictors during follow-up. <i>Transplantation</i> , <b>2013</b> , 95, 1148-53	1.8	24

77	Haemophagocytic syndrome in a liver transplant patient during treatment with Telaprevir. <i>Annals of Hepatology</i> , <b>2013</b> , 12, 974-978	3.1	7
76	Comparison of results of combined liver-kidney transplantation vs. isolated liver transplantation. <i>Annals of Hepatology</i> , <b>2013</b> , 12, 274-281	3.1	10
75	Recurrence of hepatitis C after liver transplantation. <i>Annals of Gastroenterology</i> , <b>2013</b> , 26, 304-313	2.2	32
74	Spanish society of liver transplantation (SETH) consensus recommendations on hepatitis C virus and liver transplantation. <i>Liver International</i> , <b>2012</b> , 32, 712-31	7.9	15
73	Comparison of two non-contemporaneous HCV-liver transplant cohorts: strategies to improve the efficacy of antiviral therapy. <i>Journal of Hepatology</i> , <b>2012</b> , 56, 1310-6	13.4	36
72	Liver transplantation for unresectable hepatocellular carcinoma in normal livers. <i>Journal of Hepatology</i> , <b>2012</b> , 57, 297-305	13.4	42
71	Hepatitis C virus viral kinetics during E2a or E2b pegylated interferon plus ribavirin therapy in liver transplant recipients with different immunosuppression regimes. <i>Journal of Clinical Virology</i> , <b>2012</b> , 53, 231-8	14.5	6
70	Response to different therapeutic approaches in Wilson disease. A long-term follow up study. <i>Annals of Hepatology</i> , <b>2012</b> , 11, 907-914	3.1	12
69	New developments in the management of hepatitis C virus infection: focus on boceprevir. <i>Biologics: Targets and Therapy</i> , <b>2012</b> , 6, 249-56	4.4	
68	Control of blood pressure in liver transplant recipients. <i>Transplantation</i> , <b>2012</b> , 93, 1031-7	1.8	18
67	Liver transplantation and hepatitis C. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2011</b> , 35, 805-12	2.4	49
66	Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients. <i>Journal of Hepatology</i> , <b>2011</b> , 55, 207-17	13.4	92
65	Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitis. <i>Journal of Hepatology</i> , <b>2011</b> , 55, 820-7	13.4	68
64	Treatment of hepatitis C in the post-transplant setting. <i>Digestive and Liver Disease Supplements</i> , <b>2011</b> , 5, 26-29		
63	Hot topic in hepatitis C virus research: the type of immunosuppression does not matter. <i>Liver Transplantation</i> , <b>2011</b> , 17 Suppl 3, S24-8	4.5	18
62	Anemia is not predictive of sustained virological response in liver transplant recipients with hepatitis C virus who are treated with pegylated interferon and ribavirin. <i>Liver Transplantation</i> , <b>2011</b> , 17, 1318-27	4.5	12
61	Cyclosporine a-based immunosuppression reduces relapse rate after antiviral therapy in transplanted patients with hepatitis C virus infection: a large multicenter cohort study. <i>Transplantation</i> , <b>2011</b> , 92, 334-40	1.8	31
60	Non-Markov multistate modeling using time-varying covariates, with application to progression of liver fibrosis due to hepatitis C following liver transplant. <i>International Journal of Biostatistics</i> , <b>2010</b> , 6, Article 7	1.3	16



59	94 CALCINEURIN INHIBITORS AND OUTCOME OF LIVER TRANSPLANTATION IN HCV-POSITIVE RECIPIENTS: FINAL RESULTS OF A PROSPECTIVE RANDOMIZED STUDY. <i>Journal of Hepatology</i> , <b>2010</b> , 52, S43	13.4	2
58	Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients. <i>Transplantation</i> , <b>2010</b> , 90, 1204-9	1.8	54
57	Management of Hepatitis C in Patients with End-stage Renal Disease. <i>Current Hepatitis Reports</i> , <b>2010</b> , 9, 38-46		
56	Antiviral therapy in patients with HCV-cirrhosis. <i>Annals of Hepatology</i> , <b>2009</b> , 8, 292-297	3.1	10
55	Reply:. <i>Hepatology</i> , <b>2009</b> , 49, 2126-2126	11.2	
54	Cirrhosis of mixed etiology (hepatitis C virus and alcohol): Posttransplantation outcome-Comparison with hepatitis C virus-related cirrhosis and alcoholic-related cirrhosis. <i>Liver Transplantation</i> , <b>2009</b> , 15, 79-87	4.5	47
53	Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: impact of donor age and baseline cirrhosis. <i>Liver Transplantation</i> , <b>2009</b> , 15, 738-46	4.5	57
52	Prospective validation of a noninvasive index for predicting liver fibrosis in hepatitis C virus-infected liver transplant recipients. <i>Liver Transplantation</i> , <b>2009</b> , 15, 1798-807	4.5	16
51	Comparative prospective study of two liver graft preservation solutions: University of Wisconsin and Celsior. <i>Liver Transplantation</i> , <b>2009</b> , 15, 1709-17	4.5	24
50	Indications for and results of liver retransplantation. <i>Transplantation Proceedings</i> , <b>2009</b> , 41, 1016-7	1.1	9
49	Non-invasive biomarkers of liver fibrosis in liver transplant patients with hepatitis C: can we avoid liver biopsies?. <i>Digestive and Liver Disease</i> , <b>2009</b> , 41, 226-8	3.3	9
48	Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. <i>American Journal of Transplantation</i> , <b>2008</b> , 8, 679-87	8.7	243
47	Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. <i>Journal of Hepatology</i> , <b>2008</b> , 49, 274-87	13.4	286
46	227 LONG-TERM RESULTS WITH THE USE OF GRAFTS FROM HBSAG NEGATIVE HBCAB POSITIVE DONORS IN LIVER TRANSPLANTATION. <i>Journal of Hepatology</i> , <b>2008</b> , 48, S93	13.4	30
45	Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma. <i>Liver Transplantation</i> , <b>2008</b> , 14, 1449-60	4.5	79
44	Risk of extended criteria donors in hepatitis C virus-positive recipients. <i>Liver Transplantation</i> , <b>2008</b> , 14 Suppl 2, S45-50	4.5	40
43	Treatment of chronic hepatitis C in hemodialysis patients. <i>Hepatology</i> , <b>2008</b> , 48, 1690-9	11.2	54
42	Management of hepatitis C virus in the transplant patient. <i>Clinics in Liver Disease</i> , <b>2007</b> , 11, 355-76	4.6	18

41	Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. <i>Liver Transplantation</i> , <b>2007</b> , 13, 349-60	4.5	204
40	Lessons learned from anatomic variants of the hepatic artery in 1,081 transplanted livers. <i>Liver Transplantation</i> , <b>2007</b> , 13, 1401-4	4.5	82
39	Viral hepatitis after liver transplantation. <i>Hepatology Research</i> , <b>2007</b> , 37 Suppl 2, S279-86	5.1	2
38	Optimum minimization strategies in hepatitis C virus infected liver transplant. <i>Current Opinion in Organ Transplantation</i> , <b>2007</b> , 12, 641-646	2.5	1
37	Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. <i>Liver Transplantation</i> , <b>2007</b> , 13, 21-9	4.5	134
36	Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients. <i>Liver Transplantation</i> , <b>2006</b> , 12, 762-7	4.5	66
35	Live donor liver transplantation for hepatitis C: new data, old story. <i>Liver Transplantation</i> , <b>2006</b> , 12, 516-9	4.5	9
34	Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. <i>Liver Transplantation</i> , <b>2006</b> , 12, 1067-76	4.5	131
33	Treating hepatitis C infection in liver transplant recipients. <i>Liver Transplantation</i> , <b>2006</b> , 12, 1192-204	4.5	108
32	Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. <i>Journal of Hepatology</i> , <b>2006</b> , 44, 717-22	13.4	149
31	Post-liver transplantation medical complications. <i>Annals of Hepatology</i> , <b>2006</b> , 5, 77-85	3.1	76
30	Hepatitis C virus in liver transplantation: impact and treatment of hepatitis C virus recurrence. <i>Current Opinion in Organ Transplantation</i> , <b>2006</b> , 11, 599-607	2.5	1
29	Prediction of significant fibrosis in hepatitis C virus infected liver transplant recipients by artificial neural network analysis of clinical factors. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2006</b> , 18, 1255-61	2.2	35
28	Treatment of hepatitis C after liver transplantation. <i>Clinics in Liver Disease</i> , <b>2005</b> , 9, 579-600, vi	4.6	31
27	What determines the natural history of recurrent hepatitis C after liver transplantation?. <i>Journal of Hepatology</i> , <b>2005</b> , 42, 448-56	13.4	118
26	Recurrence of hepatitis C after liver transplantation. <i>Transplantation Proceedings</i> , <b>2005</b> , 37, 3311-2	1.1	
25	Hepatitis C after liver transplantation: risk factors, outcomes, and treatment. <i>Current Opinion in Organ Transplantation</i> , <b>2005</b> , 10, 81-89	2.5	20
24	Prediction of fibrosis in HCV-infected liver transplant recipients with a simple noninvasive index. <i>Liver Transplantation</i> , <b>2005</b> , 11, 456-62	4.5	50

23	De novo internal neoplasms after liver transplantation: increased risk and aggressive behavior in recent years?. <i>American Journal of Transplantation</i> , <b>2004</b> , 4, 596-604	8.7	113
22	Genetic variability of hepatitis C virus NS3 protein in human leukocyte antigen-A2 liver transplant recipients with recurrent hepatitis C. <i>Liver Transplantation</i> , <b>2004</b> , 10, 217-27	4.5	14
21	Recurrent hepatitis C genotype 1b following liver transplantation: treatment with combination interferon-ribavirin therapy. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2004</b> , 16, 1207-12	2.2	32
20	A model to predict severe HCV-related disease following liver transplantation. <i>Hepatology</i> , <b>2003</b> , 38, 34-41	11.2	171
19	Severe recurrent hepatitis C after liver retransplantation for hepatitis C virus-related graft cirrhosis. <i>Liver Transplantation</i> , <b>2003</b> , 9, 228-35	4.5	89
18	Delayed onset of severe hepatitis C-related liver damage following liver transplantation: a matter of concern?. <i>Liver Transplantation</i> , <b>2003</b> , 9, 1152-8	4.5	41
17	Host and donor risk factors before and after liver transplantation that impact HCV recurrence. <i>Liver Transplantation</i> , <b>2003</b> , 9, S44-7	4.5	77
16	Treatment strategies for hepatitis C: intervention prior to liver transplant, pre-emptively or after established disease. <i>Clinics in Liver Disease</i> , <b>2003</b> , 7, 631-50, vii	4.6	9
15	Treatment of recurrence of hepatitis B in transplant patients. <i>Journal of Hepatology</i> , <b>2003</b> , 39 Suppl 1, S190-3	13.4	8
14	Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. <i>Hepatology</i> , <b>2002</b> , 36, 202-10	11.2	500
13	Hepatocellular carcinoma: Can it be considered a controversial indication for liver transplantation in centers with high rates of hepatitis C?. <i>Liver Transplantation</i> , <b>2002</b> , 8, 1020-7	4.5	42
12	Natural history of recurrent hepatitis C. <i>Liver Transplantation</i> , <b>2002</b> , 8, S14-8	4.5	202
11	Contribution of obesity to hepatitis C-related fibrosis progression. <i>American Journal of Gastroenterology</i> , <b>2002</b> , 97, 2408-14	0.7	172
10	De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. <i>Liver Transplantation</i> , <b>2001</b> , 7, 51-8	4.5	151
9	Are posttransplantation protocol liver biopsies useful in the long term?. <i>Liver Transplantation</i> , <b>2001</b> , 7, 790-6	4.5	104
8	Hepatitis C and liver transplantation. <i>Journal of Hepatology</i> , <b>2001</b> , 35, 666-78	13.4	231
7	Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. <i>Hepatology</i> , <b>2000</b> , 32, 852-8	11.2	432
6	HCV-related fibrosis progression following liver transplantation: increase in recent years. <i>Journal of Hepatology</i> , <b>2000</b> , 32, 673-84	13.4	642

5	Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1999</b> , 96, 5692-7	11.5	365
4	High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. <i>Hepatology</i> , <b>1999</b> , 29, 250-6	11.2	442
3	Evolution of hepatitis C virus quasispecies in patients with severe cholestatic hepatitis after liver transplantation. <i>Hepatology</i> , <b>1999</b> , 30, 1513-20	11.2	75
2	Are HCV-infected individuals candidates for hepatitis A vaccine?. <i>Lancet, The</i> , <b>1998</b> , 351, 924-5	4.0	11
1	Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection. <i>Journal of Hepatology</i> , <b>1998</b> , 28, 756-63	13.4	144